{"ticker": {"uuid": "9dd25498-e4e0-4b8f-8cbd-a6237f8996be", "symbol": "PRAX", "name": "Praxis Precision Medicines\u00a0Inc", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "Should Praxis\u2013Remagine Transdermal Patch Collaboration and FDA Review Extension Reshape PRAX Pipeline Expectations?", "summary": "Praxis Precision Medicines' collaboration with Remagine Labs to develop a transdermal patch for ulixacaltamide and the FDA's three-month extension for relutrigine's NDA review are significant developments for the company. These events could positively influence the perception of ", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-prax/praxis-precision-medicines/news/should-praxisremagine-transdermal-patch-collaboration-and-fd", "source_name": "Simply Wall Street", "published_at": "2026-07-16T03:40:58", "published_display": "16 Jul 2026 03:40", "sentiment": "positive", "sentiment_pct": 64, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Praxis Precision Medicines (PRAX) Enters Into Licensing and Research Collaboration With Remagine Labs", "summary": "Praxis Precision Medicines Inc. (PRAX) has announced a research partnership and license agreement with Remagine Labs to develop an iontophoretic transdermal patch for ulixacaltamide delivery, a T-type calcium channel inhibitor for essential tremor. This collaboration aims to leve", "url": "https://finance.yahoo.com/healthcare/articles/praxis-precision-medicines-prax-enters-140146981.html", "source_name": "Market source", "published_at": "2026-07-15T10:01:00", "published_display": "15 Jul 2026 10:01", "sentiment": "positive", "sentiment_pct": 67, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Analysts Are Bullish on Top Healthcare Stocks: Praxis Precision Medicines (PRAX), Sino Biopharmaceutical (SBMFF)", "summary": "", "url": "https://news.google.com/rss/articles/CBMimwJBVV95cUxNZUZtcXZwNHFLUndBZlJCeU5MSkJ2NlUzaTJCWmpMZWdUVmJPT3UxUTVPTzhZNDZWLXhJd1I0SkUzd1BOeXpybXRMeXhDT0dva0RKM2xldUhHYi1qQzQ4VTk5OV9xV0Q0WGRnVXYtNGRfUXIwRHJoMmRnODVvaW54ZUJod0FpdkdDeWJtSVlERm8wTEsycjlXMVZmSFdrd1ZhSkNLSEFWWWtXZVFYeFZhODlKSkp3d2ZRT3pjaHRRam1BRllEU1JKYWZpQTc4RkpxakVHTTg2a3VlZU1RWUhobDVXRm5CV01QaUlSajNFbHF3N1lfMGpWUktwTkxlU09WWDBDc3RBNlJsM25UWkJvTHYzZzhXbi0yLTRB?oc=5", "source_name": "The Globe and Mail", "published_at": "2026-07-14T12:50:00+00:00", "published_display": "14 Jul 2026 12:50", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Piper Sandler reiterates Praxis Precision Medicines stock rating By Investing.com", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwwFBVV95cUxOR2hjYWExdll4V3pYclBOdFZIQnFlcWZ2ODBaTF9UaEE0QnY2a2stNE9vZ0hFMlBhdE15emo2bmhRZWJCdkE1N2RKbFZnT1UxWWtVVk5BUEN4NUFaMWtmUmJWWWxKWGNCZ2hCYUhZX1RnNkMyQ0ZRZnZGbm9rZER4V2dwTmhaSFZVOVo1WkJEcDFxTWxUeGdUcVNrc3VGNTFXNGIycXJGblQzTm85LVpmb3ZuMEZzTmV2Y3VOWkpjSHZaczg?oc=5", "source_name": "Investing.com Nigeria", "published_at": "2026-07-13T15:28:33+00:00", "published_display": "13 Jul 2026 15:28", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Piper Sandler reiterates Praxis Precision Medicines stock rating", "summary": "Piper Sandler has reiterated an Overweight rating and $1,200 price target for Praxis Precision Medicines (NASDAQ:PRAX), citing the company's strong financial position and high (95%) probability of regulatory success for ulixacaltamide. The company has two PDUFA dates soon and ant", "url": "https://www.investing.com/news/analyst-ratings/piper-sandler-reiterates-praxis-precision-medicines-stock-rating-93CH-4788505", "source_name": "Investing.com", "published_at": "2026-07-13T13:09:57", "published_display": "13 Jul 2026 13:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Goldman Sachs Initiates Praxis Precision Medicines at Buy With $447 Price Target", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/goldman-sachs-initiates-praxis-precision-113743631.html", "source_name": "MT Newswires", "published_at": "2026-07-13T11:37:43+00:00", "published_display": "13 Jul 2026 11:37", "sentiment": "positive", "sentiment_pct": 58, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Goldman Sachs initiates Praxis Precision Medicines stock coverage with buy rating", "summary": "Goldman Sachs has initiated coverage of Praxis Precision Medicines (NASDAQ:PRAX) with a Buy rating and a price target of $447.00. The biotechnology company has two potential drug approvals expected by January 2027, including ulixacaltamide for essential tremor and relutrigine for", "url": "https://www.investing.com/news/analyst-ratings/goldman-sachs-initiates-praxis-precision-medicines-stock-coverage-with-buy-rating-93CH-4787754", "source_name": "Investing.com", "published_at": "2026-07-13T10:09:57", "published_display": "13 Jul 2026 10:09", "sentiment": "positive", "sentiment_pct": 71, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Praxis Precision Shares Rally On Price Target Hikes: Analyst Sees Upside As High As 100% For Stock", "summary": "", "url": "https://news.google.com/rss/articles/CBMitgFBVV95cUxPZ3c0dm5hU2NSZE1USngwNnRMTU5fc0dIbmFpOVVUdnZ3OHRDYjVSTzVPTk5qZFFhODZYVnpSSTRNY3NieGtkWFd4bGJyLXdWLTcwQjliRnp2WUtPdmVfQnB3X2F6S296MVBNaFNhbEljYVc0WkVvSjk2LTB4TDBqSmpKNmJoY0VpbXdDejhsYUd1YlBJbmVQeFNBS0E0czRtWnl1OWxvMkhxbHV6eWUyTkJXTmFkUQ?oc=5", "source_name": "Stocktwits", "published_at": "2026-07-12T16:32:45+00:00", "published_display": "12 Jul 2026 16:32", "sentiment": "positive", "sentiment_pct": 66, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Can Praxis Precision Medicines (PRAX) Merit A Higher Valuation As It Expands Ulixacaltamide Delivery?", "summary": "Praxis Precision Medicines (PRAX) has partnered with Remagine Labs to develop a transdermal patch for ulixacaltamide, aiming to expand its essential tremor program beyond oral delivery. Despite recent stock price momentum and a reported undervaluation narrative suggesting a fair ", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-prax/praxis-precision-medicines/news/can-praxis-precision-medicines-prax-merit-a-higher-valuation", "source_name": "Simply Wall Street", "published_at": "2026-07-10T16:09:32", "published_display": "10 Jul 2026 16:09", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Praxis Precision Medicines Seen Having Greater Commercial Upside for Relutrigine, RBC Says", "summary": "RBC Capital Markets believes Praxis Precision Medicines' relutrigine has greater commercial potential in essential tremor (ET) than in movement disorders. The analyst firm initiated coverage with an \"Outperform\" rating and a $10 price target, projecting peak sales of $1.5 billion", "url": "https://www.moomoo.com/news/post/72783050/praxis-precision-medicines-seen-having-greater-commercial-upside-for-relutrigine", "source_name": "Moomoo", "published_at": "2026-07-10T15:41:41", "published_display": "10 Jul 2026 15:41", "sentiment": "positive", "sentiment_pct": 72, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Praxis Precision Medicines explores neurology pipeline as Nasdaq-listed biotech refines its focus", "summary": "", "url": "https://news.google.com/rss/articles/CBMiygFBVV95cUxOMkd6bHJ5aG5ONFJCdDljcmljZTltTFJjNXlFX2tGZEwtQ090ejBoSkZyYmZkMVNYN2dUUGlUNUVaMkNBelA3bEM5alF2Rkh5bnZaX3VSUGlyc0daTjFTTVpNLXNCVWFyUVpBdDl5NXk2Z0NFZzVweWVWcnV6SGt3WlFwcThaVl93Qm9GUU15SWhYblppQmtrZFdnRE9sOW9jU0xoekQ0UWsxcV9YdUpJelBieWlaVnBnNm5BMk90ejRFbHdvc2tIXzNn?oc=5", "source_name": "Ad Hoc News", "published_at": "2026-07-09T12:36:32+00:00", "published_display": "09 Jul 2026 12:36", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 4 Praxis Precision Medicines Inc For: 8 July By Investing.com", "summary": "This article reports on the filing of Form 4 for Praxis Precision Medicines Inc. on July 8. It indicates that the document is available for review, likely detailing insider transactions for the company.", "url": "https://ng.investing.com/news/stock-market-news/form-4-praxis-precision-medicinesinc-for-8-july-93CH-2591844", "source_name": "Investing.com Nigeria", "published_at": "2026-07-08T22:17:03", "published_display": "08 Jul 2026 22:17", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Praxis (PRAX) CEO Marcio Souza gifts 23,121 shares, retains 56,495", "summary": "Praxis Precision Medicines, Inc. CEO Marcio Souza reported gifting a total of 23,121 shares of company common stock through bona fide gifts to the Souza 2026 Trust. These transactions, which are not market sales, included 2,600 shares previously held indirectly and 20,521 directl", "url": "https://www.stocktitan.net/sec-filings/PRAX/form-4-praxis-precision-medicines-inc-insider-trading-activity-ad59265d0b0d.html", "source_name": "Stock Titan", "published_at": "2026-07-08T20:41:38", "published_display": "08 Jul 2026 20:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Praxis Precision Medicines and Remagine Labs Announce Strategic Collaboration to Develop Transdermal Ulixacaltamide for Essential Tremor", "summary": "Praxis Precision Medicines and Remagine Labs have announced a strategic collaboration to develop an iontophoretic transdermal patch for ulixacaltamide, Praxis's lead essential tremor (ET) therapy. This aims to expand the addressable market for the drug, which recently had its New", "url": "https://www.globenewswire.com/news-release/2026/07/07/3323139/0/en/praxis-precision-medicines-and-remagine-labs-announce-strategic-collaboration-to-develop-transdermal-ulixacaltamide-for-essential-tremor.html", "source_name": "GlobeNewswire", "published_at": "2026-07-08T07:41:38", "published_display": "08 Jul 2026 07:41", "sentiment": "positive", "sentiment_pct": 93, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Ulixacaltamide Patch Collaboration and Equity Stake Altering The Investment Case For Praxis (PRAX)?", "summary": "Praxis Precision Medicines has entered a collaboration with Remagine Labs to develop a transdermal patch for ulixacaltamide to treat essential tremor, alongside an equity investment. This partnership aims to expand the delivery options for its lead asset and potentially enhance i", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-prax/praxis-precision-medicines/news/is-ulixacaltamide-patch-collaboration-and-equity-stake-alter/amp", "source_name": "Simply Wall Street", "published_at": "2026-07-08T07:39:51", "published_display": "08 Jul 2026 07:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Praxis (PRAX) teams with Remagine Labs on transdermal ulixacaltamide for essential tremor", "summary": "Praxis Precision Medicines (PRAX) has partnered with Remagine Labs to develop an iontophoretic transdermal patch for delivering ulixacaltamide to treat essential tremor. This collaboration aims to broaden the patient population for ulixacaltamide, complementing Praxis's existing ", "url": "https://www.stocktitan.net/sec-filings/PRAX/8-k-praxis-precision-medicines-inc-reports-material-event-761bfb36f046.html", "source_name": "Stock Titan", "published_at": "2026-07-07T20:40:13", "published_display": "07 Jul 2026 20:40", "sentiment": "positive", "sentiment_pct": 64, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Praxis Precision (PRAX) Partners with Remagine Labs for Innovati", "summary": "Praxis Precision Medicines Inc (PRAX) has partnered with Remagine Labs to develop an innovative transdermal patch for ulixacaltamide, a treatment for essential tremor. This collaboration aims to enhance drug delivery through iontophoresis, improving upon existing oral treatments.", "url": "https://www.gurufocus.com/news/8947270/praxis-precision-prax-partners-with-remagine-labs-for-innovative-patch-development", "source_name": "GuruFocus", "published_at": "2026-07-07T13:11:28", "published_display": "07 Jul 2026 13:11", "sentiment": "positive", "sentiment_pct": 59, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Praxis bets on skin patch for essential tremor drug", "summary": "Praxis Precision Medicines and Remagine Labs have announced a strategic collaboration to develop an iontophoretic transdermal patch for ulixacaltamide, an essential tremor (ET) drug that has received FDA Breakthrough Therapy Designation. This partnership aims to expand the treatm", "url": "https://www.stocktitan.net/news/PRAX/praxis-precision-medicines-and-remagine-labs-announce-strategic-5400nc8udm6f.html", "source_name": "Stock Titan", "published_at": "2026-07-07T12:11:28", "published_display": "07 Jul 2026 12:11", "sentiment": "positive", "sentiment_pct": 71, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)", "summary": "Praxis Precision Medicines, Inc. announced that its Board's Compensation Committee granted restricted stock unit awards for 951 shares of common stock to five new non-executive employees on July 1, 2026. These inducement grants were made under the company's 2024 Inducement Plan, ", "url": "https://finance.yahoo.com/healthcare/articles/praxis-precision-medicines-inc-announces-200100193.html", "source_name": "Market source", "published_at": "2026-07-03T05:41:00", "published_display": "03 Jul 2026 05:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Praxis Precision (NASDAQ: PRAX) replaces EY with KPMG as auditor", "summary": "Praxis Precision Medicines, Inc. announced that its Audit Committee dismissed Ernst & Young LLP (EY) and engaged KPMG LLP as its independent registered public accounting firm, effective June 29, 2026. The company stated that there were no disagreements with EY on accounting princ", "url": "https://www.stocktitan.net/sec-filings/PRAX/8-k-praxis-precision-medicines-inc-reports-material-event-978c36dcc1ca.html", "source_name": "Stock Titan", "published_at": "2026-07-02T20:10:49", "published_display": "02 Jul 2026 20:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Praxis uses inducement plan to grant 951 shares to five hires", "summary": "Praxis Precision Medicines, Inc. announced the grant of 951 restricted stock units (RSUs) to five new non-executive employees under its 2024 Inducement Plan. These RSUs, designed to attract and retain talent, will vest in four equal annual installments, in accordance with Nasdaq ", "url": "https://www.stocktitan.net/news/PRAX/praxis-precision-medicines-inc-announces-inducement-grants-under-24sh5lqrf3fb.html", "source_name": "Stock Titan", "published_at": "2026-07-02T20:10:48", "published_display": "02 Jul 2026 20:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Praxis Precision Medicines, Inc. \u2013 NASDAQ:PRAX", "summary": "This article provides access to the \"Price to sales forward\" financial data for Praxis Precision Medicines, Inc. (NASDAQ: PRAX) on TradingView. It highlights the company's financial overview within the pharmaceuticals sector and indicates that the market is currently closed with ", "url": "https://www.tradingview.com/symbols/NASDAQ-PRAX/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-07-02T04:22:07", "published_display": "02 Jul 2026 04:22", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of Praxis Precision Medicines, Inc. \u2013 NASDAQ:PRAX", "summary": "This article provides financial information for Praxis Precision Medicines, Inc. (NASDAQ: PRAX), specifically focusing on its Price to Book Forward metric. It indicates that the company's financial data is provided by reputable sources like ICE Data Services and FactSet. The cont", "url": "https://www.tradingview.com/symbols/NASDAQ-PRAX/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-06-30T19:39:28", "published_display": "30 Jun 2026 19:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBIT forward of Praxis Precision Medicines, Inc. \u2013 NASDAQ:PRAX", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqwFBVV95cUxPVGFwWnFSTWEtQmlJd3Vzbk9xbkJPUUpaSUViN3YxUUk0UHVuNjY3bFVpTllCeTYtaC04dEw0MjY2LVhmREdvR2JqVEczaGJTOE5nVDViY3FMdE5iRWNIWFVUZFJTUExWOE90eXlsM2Uxdm5kNEQ3czlUaExQUk02MEFuQ3VXQ05EMEgtVVdQUWZDUU5uZlA5T2M1VndYYzI4QlN1UmY3dGZmNFU?oc=5", "source_name": "TradingView", "published_at": "2026-06-30T07:44:39+00:00", "published_display": "30 Jun 2026 07:44", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Praxis Precision Medicines, Inc. \u2013 NASDAQ:PRAX", "summary": "This article focuses on the \"Price to earnings forward\" metric for Praxis Precision Medicines, Inc. (NASDAQ: PRAX). It appears to be a financial data page from TradingView, indicating that the market for PRAX was closed with no trades at the time of viewing.", "url": "https://www.tradingview.com/symbols/NASDAQ-PRAX/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-06-30T05:13:48", "published_display": "30 Jun 2026 05:13", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Praxis Precision Medicines stock falls on FDA review delay", "summary": "Praxis Precision Medicines (NASDAQ:PRAX) shares fell 7% after the FDA extended its review period for relutrigine by three months. The new PDUFA target action date is December 27, 2026, due to the company submitting additional sensitivity analyses of existing clinical data. Relutr", "url": "https://www.investing.com/news/stock-market-news/praxis-precision-medicines-stock-falls-on-fda-review-delay-93CH-4766329", "source_name": "Investing.com", "published_at": "2026-06-30T05:10:48", "published_display": "30 Jun 2026 05:10", "sentiment": "negative", "sentiment_pct": 31, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Praxis Precision Medicines Announces Extension Period for", "summary": "Praxis Precision Medicines announced that the FDA has extended the review period for its New Drug Application (NDA) for relutrigine by three months, setting an updated PDUFA date of December 27, 2026. This extension allows for additional time to review new sensitivity analyses of", "url": "https://www.globenewswire.com/news-release/2026/06/29/3319308/0/en/praxis-precision-medicines-announces-extension-period-for-relutrigine-for-treatment-of-scn2a-and-scn8a-developmental-and-epileptic-encephalopathies.html", "source_name": "GlobeNewswire", "published_at": "2026-06-30T04:10:15", "published_display": "30 Jun 2026 04:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Praxis Precision Medicines Says US FDA Extends Review Period for New Drug Application for Relutrigine", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/praxis-precision-medicines-says-us-210608036.html", "source_name": "MT Newswires", "published_at": "2026-06-29T21:06:08+00:00", "published_display": "29 Jun 2026 21:06", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Praxis Precision Medicines Announces Extension Period for Relutrigine for Treatment of SCN2A and SCN8A Developmental and Epileptic Encephalopathies", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/praxis-precision-medicines-announces-extension-203000138.html", "source_name": "GlobeNewswire", "published_at": "2026-06-29T20:30:00+00:00", "published_display": "29 Jun 2026 20:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "FDA extends Praxis (NASDAQ: PRAX) relutrigine review deadline to Dec 27, 2026", "summary": "The FDA has extended the review period for Praxis Precision Medicines' New Drug Application (NDA) for relutrigine by three months, moving the PDUFA target action date to December 27, 2026. This extension occurred because Praxis submitted additional sensitivity analyses of existin", "url": "https://www.stocktitan.net/sec-filings/PRAX/8-k-praxis-precision-medicines-inc-reports-material-event-99c90cb7940d.html", "source_name": "Stock Titan", "published_at": "2026-06-29T21:10:16", "published_display": "29 Jun 2026 21:10", "sentiment": "negative", "sentiment_pct": 40, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "FDA delays Praxis relutrigine review by three months to Dec. 27", "summary": "Praxis Precision Medicines announced that the FDA has extended the review period for its New Drug Application (NDA) for relutrigine by three months, shifting the PDUFA target action date from September 27, 2026, to December 27, 2026. This extension is due to a \"major amendment\" s", "url": "https://www.stocktitan.net/news/PRAX/praxis-precision-medicines-announces-extension-period-for-nvfzxh6lpq52.html", "source_name": "Stock Titan", "published_at": "2026-06-29T20:10:16", "published_display": "29 Jun 2026 20:10", "sentiment": "negative", "sentiment_pct": 39, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Praxis Precision Medicines Insider Sold Shares Worth $3,611,335, According to a Recent SEC Filing", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/praxis-precision-medicines-insider-sold-211416268.html", "source_name": "MT Newswires", "published_at": "2026-06-26T21:14:16+00:00", "published_display": "26 Jun 2026 21:14", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Praxis Precision Medicines Stock Surges 27%, With A 6-Day Winning Spree", "summary": "", "url": "https://news.google.com/rss/articles/CBMiygFBVV95cUxQYldYaDRLTjVoN3EtVXBWVFkwN0dWQjRiTTRYSEdtSXEyQ0NiNXJmZDdTM0pXNjllRzdEMEdLVGNoaWg0MTJqZTktcDctbXZZeDZjejBZc04yOEhPbkxTN3RtRksxMHBaN05EWl9sYnpfclVHTFVtTFU4SFRwUXFzQTBaVUU2dnRkbnVfVFJFYzZGaXBaN0JMRW84cnVpX2hFYkdGajRBSHRhZFFORUg5ZnNLQ2gyYklsa014WTZ3Q1RRaEIzb3NCNFZ3?oc=5", "source_name": "Trefis", "published_at": "2026-06-26T07:00:00+00:00", "published_display": "26 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Praxis (PRAX) director logs 11,600-share sale after option exercises", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwgFBVV95cUxQOUdTYmV3cFFoQ2s3QVh1SkYwU0lSck5iTVIyTWJPXy1WejFHQ2JjbzhJbkdQSVMyYVhZS3pZS2hINUpVVU0wZmpTQW1qa3FCX3c1Ynd2NXVDbmR4SlFVUlpVU3pCdUhkUklyTTRUbHFiSHA2SXo2UURTcGRIZEViS0pkSlh2VC1pS2x1Nkx6OVFJNVVoVjcxcmw2R1pCejRMS2kyb1FKejVGZks4NmZHZENWakMwNTRlMVNnbFZhekxHdw?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-26T07:00:00+00:00", "published_display": "26 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Praxis Precision Medicines (PRAX) Could Be 31% Undervalued On FDA Breakthrough Therapy News", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-06-25T07:00:00+00:00", "published_display": "25 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 144 | Praxis Precision Medicines(PRAX.US) Director Proposes to Sell 3.61 Million in Common Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMisAFBVV95cUxQTFd3cnlaX280Z0pKbENKQ1FtMF84ZFN0Zy1ydFh2RENDR2x5clp5Z3hjRnVyeTJpMUdsUVRFcTNqb3VfVkpSYmlIcjNWQVJMaGNfSk52Y2kwRkFlT2VmZDh4SmlNNUtvVmVDaklLTDlSTDk1Q2pMTVBpVGRYVDBSMFNYMnJIdTRERF90cDJ1QTRBOGZDcTd1NmZOODVONXl2QzdHc0tXRUNHYVNXWk5qbQ?oc=5", "source_name": "Moomoo", "published_at": "2026-06-24T20:20:09+00:00", "published_display": "24 Jun 2026 20:20", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[144] Praxis Precision Medicines, Inc. SEC Filing", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqwFBVV95cUxPa2lnRnNhRjRWdV9FQlNON1lLeHNuM1VDV2g5U0tERmxkX0xuWi1ldVdKeVZQVjRLeW9Cb2Z4RVo3eXhIRWhkMTVXNVpUU2NOMlREUWFrU3pNXzVHT2V0S3dLMm8tSDItR1hEeWdNZGptbWZrbDN5SmJDV29md21PREgyaHVhcENDc1JDVzR5Ym5uSFlKX2R1NEV5NHRpWlcxWmZ1S251RVZHeTg?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-24T07:00:00+00:00", "published_display": "24 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Praxis 'Strong Buy': PDUFA In Early 2027 For Ulixacaltamide And BTD Elsunersen (PRAX)", "summary": "", "url": "https://news.google.com/rss/articles/CBMitwFBVV95cUxOenVCa1NfNUZ6QVBma29QYVhQV282U3lYZUF4NE9qT1pQUW5kSWlwN3Y5TF9vMDdlSmplZDdoVVlFTmdoS3daNXplZENXSVpKdnRVU3lyb05qOWhDNTdER0oza3JnZ2owMlFQbXVzcXdUTVZ6cU9XN1pCbVJRZkdzYkhLcHZ6OTJ2cE5ueUxFZTNLRVpnNTRKNmpXdGNSQlBwWm5FQnNDQ1BwcmZiYWZBdjVTNE52NzQ?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-06-23T07:00:00+00:00", "published_display": "23 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 82, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Praxis Precision Medicines Gains After FDA Grants Breakthrough Therapy Designation", "summary": "", "url": "https://finance.yahoo.com/m/58594264-17b8-3aab-a962-d7cc0eb286c1/praxis-precision-medicines.html", "source_name": "InvestorsHub", "published_at": "2026-06-22T12:47:39+00:00", "published_display": "22 Jun 2026 12:47", "sentiment": "positive", "sentiment_pct": 58, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Praxis Precision Medicines Potential Epilepsy Treatment Receives US FDA Breakthrough Therapy Designation", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/praxis-precision-medicines-potential-epilepsy-123256460.html", "source_name": "MT Newswires", "published_at": "2026-06-22T12:32:56+00:00", "published_display": "22 Jun 2026 12:32", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "FDA gives Praxis seizure drug Breakthrough Therapy status", "summary": "", "url": "https://news.google.com/rss/articles/CBMitgFBVV95cUxQWXJaR29NZ1hJY0xiYTJScTYwNHU1Z0FVbVB1ZTl2Yjg5X1d2bDFBdXAxWm1ibF9RVV9oQXpPbzhXbFRqZi1CSHY4UThWakJCOVJEU0Rwc3hyWXN4V0NiX0xNc2lSVUFBNFJjVk9KbkhmaDVHTEZPNk5CRTAyMXN3SU8tYXRKSnNNZ08wM3EtS0NSZ054V0NaVnJpMXg0blJVUGxhNnhZa3RQM3ZKa2N2LS1xQTk3Zw?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-22T07:00:00+00:00", "published_display": "22 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Praxis Precision Medicines (PRAX) Shares Phase 2/3 POWER1 Study Findings", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqwFBVV95cUxPLTBZd0ZUbnFnQTdabUpxUEFwWkZmbURTVTc5NmFBVTZEXzloVm5Ub0FLZGJUbHRXWGV2UkxaZVM4SXpLdVQwZ0NTeXpZaG1hZm5yZTJmakVEMTR4azlnWW1VaWJPRGRNMlN2RjB2ajBJOE5FeFFEWHNpdDdUMlNvemdNQ1lLbmlQWTBUY1JGTGZKMGJFOTh1SlRRbGJHOVE4X1FCOV9qbVhPdnM?oc=5", "source_name": "Market source", "published_at": "2026-06-05T07:00:00+00:00", "published_display": "05 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Is Praxis Stock Plunging Today - Praxis Precision Medicine (NASDAQ:PRAX)", "summary": "", "url": "https://news.google.com/rss/articles/CBMi4gFBVV95cUxPMzBNbHBZWlB2UkdoMDNKU0hxTXZoRExFSWJqWFhMcU9uQ3dZUUVRRkRkU0hYR0E5elRHdVlfajdab0hYZUhsZW51RE9yVkdTcEQ3NTlpMEJWaWd3cDZrYXdJSXhhRUNhMVJxenZkaDRsN2hwZmFiMFAxSm45WlJjYWNkaGg5ckRvNnBjWVJFM1NLNlJyZU5ZZVZMaGpvdFZ6elotTUNCUzhRNW0tN0RQb2lPVW9BV04zLVM2QWoyWUpCbW1fTUFGLVN0TGs2cnk2OWRzM0N3djZyWHJxVmp1c19B?oc=5", "source_name": "Benzinga", "published_at": "2026-06-02T07:00:00+00:00", "published_display": "02 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Praxis Precision Medicines (PRAX): Best Mid Cap Stocks to Buy with Highest Upside Potential", "summary": "", "url": "https://news.google.com/rss/articles/CBMiowFBVV95cUxQaFd2bVdYRHN5c3dJbVVpWDZnMTdnTUhEU3FqeUtaSktWMlI4cTJfcWpqSzVkVFA2SjE4T3VuczBWTU1SZnZCSDVLam5oeWc1ZmZnUnFWeFlFSHFxemZ6WGhrc0ZlM3A0S0ZqWVZCSVlUYzk3Z1pISFo3UGxLWDlTcFBFbFhobXRacV8yWjNWdGM5eDlOQjFyMThjcWJ6NV9DYVJF?oc=5", "source_name": "Market source", "published_at": "2026-05-29T07:00:00+00:00", "published_display": "29 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 82, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Praxis Precision Medicines stock hits 52-week high at $358.01", "summary": "", "url": "https://news.google.com/rss/articles/CBMitgFBVV95cUxPcVBEUnkxTElZTlYzU0ZEU2RFRFdDTUFCWGw2QjByQmdSc2g4ald3ZUd2MFY0VzZhQjFWOXR5UzhSeWMtNmF3STlMV0dFU1RQSXRRbmxZR2JPblA2RnQwaUdpUHp2MWlPaWFvekl1RUFHZzdmb0I0YmkyM1J3U3QxeWU5dnFxSF9IUWZUVkV3WjcySWRfWXpFUE0wMTlaak9EVlNnZ1pDdUl6ajJ6MXdNRUwzeGsxdw?oc=5", "source_name": "Investing.com", "published_at": "2026-05-13T07:00:00+00:00", "published_display": "13 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Praxis Precision Medicines Advances Multi Asset Pipeline After FDA NDA Acceptances", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-10T07:00:00+00:00", "published_display": "10 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Is Praxis Precision Medicines (PRAX) Pricing In Its 10x One Year Surge?", "summary": "", "url": "https://news.google.com/rss/articles/CBMi8gFBVV95cUxQY2ZXUUpxSDRhWDRmNXZvVU1PQTNWRk5oSGo2V2ctNFRRZlNJS3BhaTFvWjFTMUN6WTJsXzNLN0ZhMzZkbzlyRXU2SUlCRTRiQ2Q0TlZKWkFBTkRtb242Q2c4NHYyV0pnalIwLW9MSjY0VmhhQVdMUnpTbHpuNlFwUWFHZFZjNkxIWEFFdW85QnZwZjhQU1FQZHlwbWJDM1NqdTFyemg1a084Vk02SklhN3JFdDZNWkQ5RWczdTJDZlVBZnVGcjF2RHVLRUlRVVdWS003OXBwQ3RqaXdTVXNDaWliVWpXc0JIWng1aWlnMktsZ9IB9wFBVV95cUxNelFzYU5IYVNaQ0p5elNDR2xqTk03RDRFZzc5ZDhnWlFiN2gzSlV5UkxIZXpLc2JNQ2xNem9oVVpzZmtodF95UUdpUUF6LWNYMWJiNTNLWnljVHZiS1ptNHhuNG1zanhWN1R2V2N6OW9uM0tENXFEdWtrZV9DMTZMdjNzTWRscFdzd2UwcVh4VjN6amx3WmhsNzFFdG9nTFVXSGFjbk9sMlEwMzNxclczWGUzWDJ3VjUzZENUdmowSXpTZ0ZjeGcyUkM5YS15bU9pc1pjNjdsVHlITUJuU2hjQXUzeGNkOEVtZUhXMTFGTktrcUl6Q0VN?oc=5", "source_name": "simplywall.st", "published_at": "2026-04-16T07:00:00+00:00", "published_display": "16 Apr 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Is Praxis Precision Medicines (PRAX) Still Attractive After Its Big Share Price Run?", "summary": "", "url": "https://news.google.com/rss/articles/CBMiiwFBVV95cUxOSEJVMVBBVlh2djZkVXBaZ2xGeTFRM0hrQkFXWE12MlhhVlpydWQ1Z2pzQVg0MTA4aGtTRWZjcnBzLVJWd0hhWWY1M2hqbHpkRmxlTWtwOTN0aE5JYVEzMERWT040UzJjb0NsOXJ2MTQ3aDFQWTYzeEdPLWFyRUphVVlKZElMZFozRlM0?oc=5", "source_name": "Market source", "published_at": "2026-03-15T07:00:00+00:00", "published_display": "15 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is It Too Late To Reassess Praxis Precision Medicines (PRAX) After Its 1-Year Surge?", "summary": "", "url": "https://news.google.com/rss/articles/CBMijgFBVV95cUxPTUdnbTQ2NFlRSmN3Ml95a0loNmgtUngxbm1qQ1lFbVZQVFhzQmRobGVyTnA0Mi04S2EyTElxbmZfTHg0TGFjWks3cno2MHJmanlNbXRnb0tFZVZaUzRWNWlWdTUtQXk1WVVQSXR0cTBzVC1HTktkblIwR2g2NldkWkhrSEVFSmpHdHRoOW9B?oc=5", "source_name": "Market source", "published_at": "2026-01-14T08:00:00+00:00", "published_display": "14 Jan 2026 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "Should Praxis\u2013Remagine Transdermal Patch Collaboration and FDA Review Extension Reshape PRAX Pipeline Expectations?", "summary": "Praxis Precision Medicines' collaboration with Remagine Labs to develop a transdermal patch for ulixacaltamide and the FDA's three-month extension for relutrigine's NDA review are significant developments for the company. These events could positively influence the perception of ", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-prax/praxis-precision-medicines/news/should-praxisremagine-transdermal-patch-collaboration-and-fd", "source_name": "Simply Wall Street", "published_at": "2026-07-16T03:40:58", "published_display": "16 Jul 2026 03:40", "sentiment": "positive", "sentiment_pct": 64, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Praxis Precision Medicines (PRAX) Enters Into Licensing and Research Collaboration With Remagine Labs", "summary": "Praxis Precision Medicines Inc. (PRAX) has announced a research partnership and license agreement with Remagine Labs to develop an iontophoretic transdermal patch for ulixacaltamide delivery, a T-type calcium channel inhibitor for essential tremor. This collaboration aims to leve", "url": "https://finance.yahoo.com/healthcare/articles/praxis-precision-medicines-prax-enters-140146981.html", "source_name": "Market source", "published_at": "2026-07-15T10:01:00", "published_display": "15 Jul 2026 10:01", "sentiment": "positive", "sentiment_pct": 67, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Analysts Are Bullish on Top Healthcare Stocks: Praxis Precision Medicines (PRAX), Sino Biopharmaceutical (SBMFF)", "summary": "", "url": "https://news.google.com/rss/articles/CBMimwJBVV95cUxNZUZtcXZwNHFLUndBZlJCeU5MSkJ2NlUzaTJCWmpMZWdUVmJPT3UxUTVPTzhZNDZWLXhJd1I0SkUzd1BOeXpybXRMeXhDT0dva0RKM2xldUhHYi1qQzQ4VTk5OV9xV0Q0WGRnVXYtNGRfUXIwRHJoMmRnODVvaW54ZUJod0FpdkdDeWJtSVlERm8wTEsycjlXMVZmSFdrd1ZhSkNLSEFWWWtXZVFYeFZhODlKSkp3d2ZRT3pjaHRRam1BRllEU1JKYWZpQTc4RkpxakVHTTg2a3VlZU1RWUhobDVXRm5CV01QaUlSajNFbHF3N1lfMGpWUktwTkxlU09WWDBDc3RBNlJsM25UWkJvTHYzZzhXbi0yLTRB?oc=5", "source_name": "The Globe and Mail", "published_at": "2026-07-14T12:50:00+00:00", "published_display": "14 Jul 2026 12:50", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Piper Sandler reiterates Praxis Precision Medicines stock rating By Investing.com", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwwFBVV95cUxOR2hjYWExdll4V3pYclBOdFZIQnFlcWZ2ODBaTF9UaEE0QnY2a2stNE9vZ0hFMlBhdE15emo2bmhRZWJCdkE1N2RKbFZnT1UxWWtVVk5BUEN4NUFaMWtmUmJWWWxKWGNCZ2hCYUhZX1RnNkMyQ0ZRZnZGbm9rZER4V2dwTmhaSFZVOVo1WkJEcDFxTWxUeGdUcVNrc3VGNTFXNGIycXJGblQzTm85LVpmb3ZuMEZzTmV2Y3VOWkpjSHZaczg?oc=5", "source_name": "Investing.com Nigeria", "published_at": "2026-07-13T15:28:33+00:00", "published_display": "13 Jul 2026 15:28", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Piper Sandler reiterates Praxis Precision Medicines stock rating", "summary": "Piper Sandler has reiterated an Overweight rating and $1,200 price target for Praxis Precision Medicines (NASDAQ:PRAX), citing the company's strong financial position and high (95%) probability of regulatory success for ulixacaltamide. The company has two PDUFA dates soon and ant", "url": "https://www.investing.com/news/analyst-ratings/piper-sandler-reiterates-praxis-precision-medicines-stock-rating-93CH-4788505", "source_name": "Investing.com", "published_at": "2026-07-13T13:09:57", "published_display": "13 Jul 2026 13:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Goldman Sachs Initiates Praxis Precision Medicines at Buy With $447 Price Target", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/goldman-sachs-initiates-praxis-precision-113743631.html", "source_name": "MT Newswires", "published_at": "2026-07-13T11:37:43+00:00", "published_display": "13 Jul 2026 11:37", "sentiment": "positive", "sentiment_pct": 58, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Goldman Sachs initiates Praxis Precision Medicines stock coverage with buy rating", "summary": "Goldman Sachs has initiated coverage of Praxis Precision Medicines (NASDAQ:PRAX) with a Buy rating and a price target of $447.00. The biotechnology company has two potential drug approvals expected by January 2027, including ulixacaltamide for essential tremor and relutrigine for", "url": "https://www.investing.com/news/analyst-ratings/goldman-sachs-initiates-praxis-precision-medicines-stock-coverage-with-buy-rating-93CH-4787754", "source_name": "Investing.com", "published_at": "2026-07-13T10:09:57", "published_display": "13 Jul 2026 10:09", "sentiment": "positive", "sentiment_pct": 71, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Praxis Precision Shares Rally On Price Target Hikes: Analyst Sees Upside As High As 100% For Stock", "summary": "", "url": "https://news.google.com/rss/articles/CBMitgFBVV95cUxPZ3c0dm5hU2NSZE1USngwNnRMTU5fc0dIbmFpOVVUdnZ3OHRDYjVSTzVPTk5qZFFhODZYVnpSSTRNY3NieGtkWFd4bGJyLXdWLTcwQjliRnp2WUtPdmVfQnB3X2F6S296MVBNaFNhbEljYVc0WkVvSjk2LTB4TDBqSmpKNmJoY0VpbXdDejhsYUd1YlBJbmVQeFNBS0E0czRtWnl1OWxvMkhxbHV6eWUyTkJXTmFkUQ?oc=5", "source_name": "Stocktwits", "published_at": "2026-07-12T16:32:45+00:00", "published_display": "12 Jul 2026 16:32", "sentiment": "positive", "sentiment_pct": 66, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Can Praxis Precision Medicines (PRAX) Merit A Higher Valuation As It Expands Ulixacaltamide Delivery?", "summary": "Praxis Precision Medicines (PRAX) has partnered with Remagine Labs to develop a transdermal patch for ulixacaltamide, aiming to expand its essential tremor program beyond oral delivery. Despite recent stock price momentum and a reported undervaluation narrative suggesting a fair ", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-prax/praxis-precision-medicines/news/can-praxis-precision-medicines-prax-merit-a-higher-valuation", "source_name": "Simply Wall Street", "published_at": "2026-07-10T16:09:32", "published_display": "10 Jul 2026 16:09", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Praxis Precision Medicines Seen Having Greater Commercial Upside for Relutrigine, RBC Says", "summary": "RBC Capital Markets believes Praxis Precision Medicines' relutrigine has greater commercial potential in essential tremor (ET) than in movement disorders. The analyst firm initiated coverage with an \"Outperform\" rating and a $10 price target, projecting peak sales of $1.5 billion", "url": "https://www.moomoo.com/news/post/72783050/praxis-precision-medicines-seen-having-greater-commercial-upside-for-relutrigine", "source_name": "Moomoo", "published_at": "2026-07-10T15:41:41", "published_display": "10 Jul 2026 15:41", "sentiment": "positive", "sentiment_pct": 72, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Praxis Precision Medicines explores neurology pipeline as Nasdaq-listed biotech refines its focus", "summary": "", "url": "https://news.google.com/rss/articles/CBMiygFBVV95cUxOMkd6bHJ5aG5ONFJCdDljcmljZTltTFJjNXlFX2tGZEwtQ090ejBoSkZyYmZkMVNYN2dUUGlUNUVaMkNBelA3bEM5alF2Rkh5bnZaX3VSUGlyc0daTjFTTVpNLXNCVWFyUVpBdDl5NXk2Z0NFZzVweWVWcnV6SGt3WlFwcThaVl93Qm9GUU15SWhYblppQmtrZFdnRE9sOW9jU0xoekQ0UWsxcV9YdUpJelBieWlaVnBnNm5BMk90ejRFbHdvc2tIXzNn?oc=5", "source_name": "Ad Hoc News", "published_at": "2026-07-09T12:36:32+00:00", "published_display": "09 Jul 2026 12:36", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 4 Praxis Precision Medicines Inc For: 8 July By Investing.com", "summary": "This article reports on the filing of Form 4 for Praxis Precision Medicines Inc. on July 8. It indicates that the document is available for review, likely detailing insider transactions for the company.", "url": "https://ng.investing.com/news/stock-market-news/form-4-praxis-precision-medicinesinc-for-8-july-93CH-2591844", "source_name": "Investing.com Nigeria", "published_at": "2026-07-08T22:17:03", "published_display": "08 Jul 2026 22:17", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Praxis (PRAX) CEO Marcio Souza gifts 23,121 shares, retains 56,495", "summary": "Praxis Precision Medicines, Inc. CEO Marcio Souza reported gifting a total of 23,121 shares of company common stock through bona fide gifts to the Souza 2026 Trust. These transactions, which are not market sales, included 2,600 shares previously held indirectly and 20,521 directl", "url": "https://www.stocktitan.net/sec-filings/PRAX/form-4-praxis-precision-medicines-inc-insider-trading-activity-ad59265d0b0d.html", "source_name": "Stock Titan", "published_at": "2026-07-08T20:41:38", "published_display": "08 Jul 2026 20:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Praxis Precision Medicines and Remagine Labs Announce Strategic Collaboration to Develop Transdermal Ulixacaltamide for Essential Tremor", "summary": "Praxis Precision Medicines and Remagine Labs have announced a strategic collaboration to develop an iontophoretic transdermal patch for ulixacaltamide, Praxis's lead essential tremor (ET) therapy. This aims to expand the addressable market for the drug, which recently had its New", "url": "https://www.globenewswire.com/news-release/2026/07/07/3323139/0/en/praxis-precision-medicines-and-remagine-labs-announce-strategic-collaboration-to-develop-transdermal-ulixacaltamide-for-essential-tremor.html", "source_name": "GlobeNewswire", "published_at": "2026-07-08T07:41:38", "published_display": "08 Jul 2026 07:41", "sentiment": "positive", "sentiment_pct": 93, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Ulixacaltamide Patch Collaboration and Equity Stake Altering The Investment Case For Praxis (PRAX)?", "summary": "Praxis Precision Medicines has entered a collaboration with Remagine Labs to develop a transdermal patch for ulixacaltamide to treat essential tremor, alongside an equity investment. This partnership aims to expand the delivery options for its lead asset and potentially enhance i", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-prax/praxis-precision-medicines/news/is-ulixacaltamide-patch-collaboration-and-equity-stake-alter/amp", "source_name": "Simply Wall Street", "published_at": "2026-07-08T07:39:51", "published_display": "08 Jul 2026 07:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Praxis (PRAX) teams with Remagine Labs on transdermal ulixacaltamide for essential tremor", "summary": "Praxis Precision Medicines (PRAX) has partnered with Remagine Labs to develop an iontophoretic transdermal patch for delivering ulixacaltamide to treat essential tremor. This collaboration aims to broaden the patient population for ulixacaltamide, complementing Praxis's existing ", "url": "https://www.stocktitan.net/sec-filings/PRAX/8-k-praxis-precision-medicines-inc-reports-material-event-761bfb36f046.html", "source_name": "Stock Titan", "published_at": "2026-07-07T20:40:13", "published_display": "07 Jul 2026 20:40", "sentiment": "positive", "sentiment_pct": 64, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Praxis Precision (PRAX) Partners with Remagine Labs for Innovati", "summary": "Praxis Precision Medicines Inc (PRAX) has partnered with Remagine Labs to develop an innovative transdermal patch for ulixacaltamide, a treatment for essential tremor. This collaboration aims to enhance drug delivery through iontophoresis, improving upon existing oral treatments.", "url": "https://www.gurufocus.com/news/8947270/praxis-precision-prax-partners-with-remagine-labs-for-innovative-patch-development", "source_name": "GuruFocus", "published_at": "2026-07-07T13:11:28", "published_display": "07 Jul 2026 13:11", "sentiment": "positive", "sentiment_pct": 59, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Praxis bets on skin patch for essential tremor drug", "summary": "Praxis Precision Medicines and Remagine Labs have announced a strategic collaboration to develop an iontophoretic transdermal patch for ulixacaltamide, an essential tremor (ET) drug that has received FDA Breakthrough Therapy Designation. This partnership aims to expand the treatm", "url": "https://www.stocktitan.net/news/PRAX/praxis-precision-medicines-and-remagine-labs-announce-strategic-5400nc8udm6f.html", "source_name": "Stock Titan", "published_at": "2026-07-07T12:11:28", "published_display": "07 Jul 2026 12:11", "sentiment": "positive", "sentiment_pct": 71, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)", "summary": "Praxis Precision Medicines, Inc. announced that its Board's Compensation Committee granted restricted stock unit awards for 951 shares of common stock to five new non-executive employees on July 1, 2026. These inducement grants were made under the company's 2024 Inducement Plan, ", "url": "https://finance.yahoo.com/healthcare/articles/praxis-precision-medicines-inc-announces-200100193.html", "source_name": "Market source", "published_at": "2026-07-03T05:41:00", "published_display": "03 Jul 2026 05:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Praxis Precision (NASDAQ: PRAX) replaces EY with KPMG as auditor", "summary": "Praxis Precision Medicines, Inc. announced that its Audit Committee dismissed Ernst & Young LLP (EY) and engaged KPMG LLP as its independent registered public accounting firm, effective June 29, 2026. The company stated that there were no disagreements with EY on accounting princ", "url": "https://www.stocktitan.net/sec-filings/PRAX/8-k-praxis-precision-medicines-inc-reports-material-event-978c36dcc1ca.html", "source_name": "Stock Titan", "published_at": "2026-07-02T20:10:49", "published_display": "02 Jul 2026 20:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Praxis uses inducement plan to grant 951 shares to five hires", "summary": "Praxis Precision Medicines, Inc. announced the grant of 951 restricted stock units (RSUs) to five new non-executive employees under its 2024 Inducement Plan. These RSUs, designed to attract and retain talent, will vest in four equal annual installments, in accordance with Nasdaq ", "url": "https://www.stocktitan.net/news/PRAX/praxis-precision-medicines-inc-announces-inducement-grants-under-24sh5lqrf3fb.html", "source_name": "Stock Titan", "published_at": "2026-07-02T20:10:48", "published_display": "02 Jul 2026 20:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Praxis Precision Medicines, Inc. \u2013 NASDAQ:PRAX", "summary": "This article provides access to the \"Price to sales forward\" financial data for Praxis Precision Medicines, Inc. (NASDAQ: PRAX) on TradingView. It highlights the company's financial overview within the pharmaceuticals sector and indicates that the market is currently closed with ", "url": "https://www.tradingview.com/symbols/NASDAQ-PRAX/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-07-02T04:22:07", "published_display": "02 Jul 2026 04:22", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of Praxis Precision Medicines, Inc. \u2013 NASDAQ:PRAX", "summary": "This article provides financial information for Praxis Precision Medicines, Inc. (NASDAQ: PRAX), specifically focusing on its Price to Book Forward metric. It indicates that the company's financial data is provided by reputable sources like ICE Data Services and FactSet. The cont", "url": "https://www.tradingview.com/symbols/NASDAQ-PRAX/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-06-30T19:39:28", "published_display": "30 Jun 2026 19:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBIT forward of Praxis Precision Medicines, Inc. \u2013 NASDAQ:PRAX", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqwFBVV95cUxPVGFwWnFSTWEtQmlJd3Vzbk9xbkJPUUpaSUViN3YxUUk0UHVuNjY3bFVpTllCeTYtaC04dEw0MjY2LVhmREdvR2JqVEczaGJTOE5nVDViY3FMdE5iRWNIWFVUZFJTUExWOE90eXlsM2Uxdm5kNEQ3czlUaExQUk02MEFuQ3VXQ05EMEgtVVdQUWZDUU5uZlA5T2M1VndYYzI4QlN1UmY3dGZmNFU?oc=5", "source_name": "TradingView", "published_at": "2026-06-30T07:44:39+00:00", "published_display": "30 Jun 2026 07:44", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Praxis Precision Medicines, Inc. \u2013 NASDAQ:PRAX", "summary": "This article focuses on the \"Price to earnings forward\" metric for Praxis Precision Medicines, Inc. (NASDAQ: PRAX). It appears to be a financial data page from TradingView, indicating that the market for PRAX was closed with no trades at the time of viewing.", "url": "https://www.tradingview.com/symbols/NASDAQ-PRAX/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-06-30T05:13:48", "published_display": "30 Jun 2026 05:13", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Praxis Precision Medicines stock falls on FDA review delay", "summary": "Praxis Precision Medicines (NASDAQ:PRAX) shares fell 7% after the FDA extended its review period for relutrigine by three months. The new PDUFA target action date is December 27, 2026, due to the company submitting additional sensitivity analyses of existing clinical data. Relutr", "url": "https://www.investing.com/news/stock-market-news/praxis-precision-medicines-stock-falls-on-fda-review-delay-93CH-4766329", "source_name": "Investing.com", "published_at": "2026-06-30T05:10:48", "published_display": "30 Jun 2026 05:10", "sentiment": "negative", "sentiment_pct": 31, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Praxis Precision Medicines Announces Extension Period for", "summary": "Praxis Precision Medicines announced that the FDA has extended the review period for its New Drug Application (NDA) for relutrigine by three months, setting an updated PDUFA date of December 27, 2026. This extension allows for additional time to review new sensitivity analyses of", "url": "https://www.globenewswire.com/news-release/2026/06/29/3319308/0/en/praxis-precision-medicines-announces-extension-period-for-relutrigine-for-treatment-of-scn2a-and-scn8a-developmental-and-epileptic-encephalopathies.html", "source_name": "GlobeNewswire", "published_at": "2026-06-30T04:10:15", "published_display": "30 Jun 2026 04:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Praxis Precision Medicines Says US FDA Extends Review Period for New Drug Application for Relutrigine", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/praxis-precision-medicines-says-us-210608036.html", "source_name": "MT Newswires", "published_at": "2026-06-29T21:06:08+00:00", "published_display": "29 Jun 2026 21:06", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Praxis Precision Medicines Announces Extension Period for Relutrigine for Treatment of SCN2A and SCN8A Developmental and Epileptic Encephalopathies", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/praxis-precision-medicines-announces-extension-203000138.html", "source_name": "GlobeNewswire", "published_at": "2026-06-29T20:30:00+00:00", "published_display": "29 Jun 2026 20:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "FDA extends Praxis (NASDAQ: PRAX) relutrigine review deadline to Dec 27, 2026", "summary": "The FDA has extended the review period for Praxis Precision Medicines' New Drug Application (NDA) for relutrigine by three months, moving the PDUFA target action date to December 27, 2026. This extension occurred because Praxis submitted additional sensitivity analyses of existin", "url": "https://www.stocktitan.net/sec-filings/PRAX/8-k-praxis-precision-medicines-inc-reports-material-event-99c90cb7940d.html", "source_name": "Stock Titan", "published_at": "2026-06-29T21:10:16", "published_display": "29 Jun 2026 21:10", "sentiment": "negative", "sentiment_pct": 40, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "FDA delays Praxis relutrigine review by three months to Dec. 27", "summary": "Praxis Precision Medicines announced that the FDA has extended the review period for its New Drug Application (NDA) for relutrigine by three months, shifting the PDUFA target action date from September 27, 2026, to December 27, 2026. This extension is due to a \"major amendment\" s", "url": "https://www.stocktitan.net/news/PRAX/praxis-precision-medicines-announces-extension-period-for-nvfzxh6lpq52.html", "source_name": "Stock Titan", "published_at": "2026-06-29T20:10:16", "published_display": "29 Jun 2026 20:10", "sentiment": "negative", "sentiment_pct": 39, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Praxis Precision Medicines Insider Sold Shares Worth $3,611,335, According to a Recent SEC Filing", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/praxis-precision-medicines-insider-sold-211416268.html", "source_name": "MT Newswires", "published_at": "2026-06-26T21:14:16+00:00", "published_display": "26 Jun 2026 21:14", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Praxis Precision Medicines Stock Surges 27%, With A 6-Day Winning Spree", "summary": "", "url": "https://news.google.com/rss/articles/CBMiygFBVV95cUxQYldYaDRLTjVoN3EtVXBWVFkwN0dWQjRiTTRYSEdtSXEyQ0NiNXJmZDdTM0pXNjllRzdEMEdLVGNoaWg0MTJqZTktcDctbXZZeDZjejBZc04yOEhPbkxTN3RtRksxMHBaN05EWl9sYnpfclVHTFVtTFU4SFRwUXFzQTBaVUU2dnRkbnVfVFJFYzZGaXBaN0JMRW84cnVpX2hFYkdGajRBSHRhZFFORUg5ZnNLQ2gyYklsa014WTZ3Q1RRaEIzb3NCNFZ3?oc=5", "source_name": "Trefis", "published_at": "2026-06-26T07:00:00+00:00", "published_display": "26 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Praxis (PRAX) director logs 11,600-share sale after option exercises", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwgFBVV95cUxQOUdTYmV3cFFoQ2s3QVh1SkYwU0lSck5iTVIyTWJPXy1WejFHQ2JjbzhJbkdQSVMyYVhZS3pZS2hINUpVVU0wZmpTQW1qa3FCX3c1Ynd2NXVDbmR4SlFVUlpVU3pCdUhkUklyTTRUbHFiSHA2SXo2UURTcGRIZEViS0pkSlh2VC1pS2x1Nkx6OVFJNVVoVjcxcmw2R1pCejRMS2kyb1FKejVGZks4NmZHZENWakMwNTRlMVNnbFZhekxHdw?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-26T07:00:00+00:00", "published_display": "26 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Praxis Precision Medicines (PRAX) Could Be 31% Undervalued On FDA Breakthrough Therapy News", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-06-25T07:00:00+00:00", "published_display": "25 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 144 | Praxis Precision Medicines(PRAX.US) Director Proposes to Sell 3.61 Million in Common Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMisAFBVV95cUxQTFd3cnlaX280Z0pKbENKQ1FtMF84ZFN0Zy1ydFh2RENDR2x5clp5Z3hjRnVyeTJpMUdsUVRFcTNqb3VfVkpSYmlIcjNWQVJMaGNfSk52Y2kwRkFlT2VmZDh4SmlNNUtvVmVDaklLTDlSTDk1Q2pMTVBpVGRYVDBSMFNYMnJIdTRERF90cDJ1QTRBOGZDcTd1NmZOODVONXl2QzdHc0tXRUNHYVNXWk5qbQ?oc=5", "source_name": "Moomoo", "published_at": "2026-06-24T20:20:09+00:00", "published_display": "24 Jun 2026 20:20", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[144] Praxis Precision Medicines, Inc. SEC Filing", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqwFBVV95cUxPa2lnRnNhRjRWdV9FQlNON1lLeHNuM1VDV2g5U0tERmxkX0xuWi1ldVdKeVZQVjRLeW9Cb2Z4RVo3eXhIRWhkMTVXNVpUU2NOMlREUWFrU3pNXzVHT2V0S3dLMm8tSDItR1hEeWdNZGptbWZrbDN5SmJDV29md21PREgyaHVhcENDc1JDVzR5Ym5uSFlKX2R1NEV5NHRpWlcxWmZ1S251RVZHeTg?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-24T07:00:00+00:00", "published_display": "24 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Praxis 'Strong Buy': PDUFA In Early 2027 For Ulixacaltamide And BTD Elsunersen (PRAX)", "summary": "", "url": "https://news.google.com/rss/articles/CBMitwFBVV95cUxOenVCa1NfNUZ6QVBma29QYVhQV282U3lYZUF4NE9qT1pQUW5kSWlwN3Y5TF9vMDdlSmplZDdoVVlFTmdoS3daNXplZENXSVpKdnRVU3lyb05qOWhDNTdER0oza3JnZ2owMlFQbXVzcXdUTVZ6cU9XN1pCbVJRZkdzYkhLcHZ6OTJ2cE5ueUxFZTNLRVpnNTRKNmpXdGNSQlBwWm5FQnNDQ1BwcmZiYWZBdjVTNE52NzQ?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-06-23T07:00:00+00:00", "published_display": "23 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 82, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Praxis Precision Medicines Gains After FDA Grants Breakthrough Therapy Designation", "summary": "", "url": "https://finance.yahoo.com/m/58594264-17b8-3aab-a962-d7cc0eb286c1/praxis-precision-medicines.html", "source_name": "InvestorsHub", "published_at": "2026-06-22T12:47:39+00:00", "published_display": "22 Jun 2026 12:47", "sentiment": "positive", "sentiment_pct": 58, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Praxis Precision Medicines Potential Epilepsy Treatment Receives US FDA Breakthrough Therapy Designation", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/praxis-precision-medicines-potential-epilepsy-123256460.html", "source_name": "MT Newswires", "published_at": "2026-06-22T12:32:56+00:00", "published_display": "22 Jun 2026 12:32", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "FDA gives Praxis seizure drug Breakthrough Therapy status", "summary": "", "url": "https://news.google.com/rss/articles/CBMitgFBVV95cUxQWXJaR29NZ1hJY0xiYTJScTYwNHU1Z0FVbVB1ZTl2Yjg5X1d2bDFBdXAxWm1ibF9RVV9oQXpPbzhXbFRqZi1CSHY4UThWakJCOVJEU0Rwc3hyWXN4V0NiX0xNc2lSVUFBNFJjVk9KbkhmaDVHTEZPNk5CRTAyMXN3SU8tYXRKSnNNZ08wM3EtS0NSZ054V0NaVnJpMXg0blJVUGxhNnhZa3RQM3ZKa2N2LS1xQTk3Zw?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-22T07:00:00+00:00", "published_display": "22 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Praxis Precision Medicines (PRAX) Shares Phase 2/3 POWER1 Study Findings", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqwFBVV95cUxPLTBZd0ZUbnFnQTdabUpxUEFwWkZmbURTVTc5NmFBVTZEXzloVm5Ub0FLZGJUbHRXWGV2UkxaZVM4SXpLdVQwZ0NTeXpZaG1hZm5yZTJmakVEMTR4azlnWW1VaWJPRGRNMlN2RjB2ajBJOE5FeFFEWHNpdDdUMlNvemdNQ1lLbmlQWTBUY1JGTGZKMGJFOTh1SlRRbGJHOVE4X1FCOV9qbVhPdnM?oc=5", "source_name": "Market source", "published_at": "2026-06-05T07:00:00+00:00", "published_display": "05 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Is Praxis Stock Plunging Today - Praxis Precision Medicine (NASDAQ:PRAX)", "summary": "", "url": "https://news.google.com/rss/articles/CBMi4gFBVV95cUxPMzBNbHBZWlB2UkdoMDNKU0hxTXZoRExFSWJqWFhMcU9uQ3dZUUVRRkRkU0hYR0E5elRHdVlfajdab0hYZUhsZW51RE9yVkdTcEQ3NTlpMEJWaWd3cDZrYXdJSXhhRUNhMVJxenZkaDRsN2hwZmFiMFAxSm45WlJjYWNkaGg5ckRvNnBjWVJFM1NLNlJyZU5ZZVZMaGpvdFZ6elotTUNCUzhRNW0tN0RQb2lPVW9BV04zLVM2QWoyWUpCbW1fTUFGLVN0TGs2cnk2OWRzM0N3djZyWHJxVmp1c19B?oc=5", "source_name": "Benzinga", "published_at": "2026-06-02T07:00:00+00:00", "published_display": "02 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Praxis Precision Medicines (PRAX): Best Mid Cap Stocks to Buy with Highest Upside Potential", "summary": "", "url": "https://news.google.com/rss/articles/CBMiowFBVV95cUxQaFd2bVdYRHN5c3dJbVVpWDZnMTdnTUhEU3FqeUtaSktWMlI4cTJfcWpqSzVkVFA2SjE4T3VuczBWTU1SZnZCSDVLam5oeWc1ZmZnUnFWeFlFSHFxemZ6WGhrc0ZlM3A0S0ZqWVZCSVlUYzk3Z1pISFo3UGxLWDlTcFBFbFhobXRacV8yWjNWdGM5eDlOQjFyMThjcWJ6NV9DYVJF?oc=5", "source_name": "Market source", "published_at": "2026-05-29T07:00:00+00:00", "published_display": "29 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 82, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Praxis Precision Medicines stock hits 52-week high at $358.01", "summary": "", "url": "https://news.google.com/rss/articles/CBMitgFBVV95cUxPcVBEUnkxTElZTlYzU0ZEU2RFRFdDTUFCWGw2QjByQmdSc2g4ald3ZUd2MFY0VzZhQjFWOXR5UzhSeWMtNmF3STlMV0dFU1RQSXRRbmxZR2JPblA2RnQwaUdpUHp2MWlPaWFvekl1RUFHZzdmb0I0YmkyM1J3U3QxeWU5dnFxSF9IUWZUVkV3WjcySWRfWXpFUE0wMTlaak9EVlNnZ1pDdUl6ajJ6MXdNRUwzeGsxdw?oc=5", "source_name": "Investing.com", "published_at": "2026-05-13T07:00:00+00:00", "published_display": "13 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Praxis Precision Medicines Advances Multi Asset Pipeline After FDA NDA Acceptances", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-10T07:00:00+00:00", "published_display": "10 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Praxis Precision Medicines (PRAX) Pricing In Its 10x One Year Surge?", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-04-16T07:00:00+00:00", "published_display": "16 Apr 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Praxis Precision Medicines (PRAX) Still Attractive After Its Big Share Price Run?", "summary": "", "url": "https://news.google.com/rss/articles/CBMiiwFBVV95cUxOSEJVMVBBVlh2djZkVXBaZ2xGeTFRM0hrQkFXWE12MlhhVlpydWQ1Z2pzQVg0MTA4aGtTRWZjcnBzLVJWd0hhWWY1M2hqbHpkRmxlTWtwOTN0aE5JYVEzMERWT040UzJjb0NsOXJ2MTQ3aDFQWTYzeEdPLWFyRUphVVlKZElMZFozRlM0?oc=5", "source_name": "Market source", "published_at": "2026-03-15T07:00:00+00:00", "published_display": "15 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is It Too Late To Reassess Praxis Precision Medicines (PRAX) After Its 1-Year Surge?", "summary": "", "url": "https://news.google.com/rss/articles/CBMijgFBVV95cUxPTUdnbTQ2NFlRSmN3Ml95a0loNmgtUngxbm1qQ1lFbVZQVFhzQmRobGVyTnA0Mi04S2EyTElxbmZfTHg0TGFjWks3cno2MHJmanlNbXRnb0tFZVZaUzRWNWlWdTUtQXk1WVVQSXR0cTBzVC1HTktkblIwR2g2NldkWkhrSEVFSmpHdHRoOW9B?oc=5", "source_name": "Market source", "published_at": "2026-01-14T08:00:00+00:00", "published_display": "14 Jan 2026 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 94, "total_relevant": 57, "sentiment_summary": {"positive": 19, "negative": 5, "neutral": 33, "score": 56, "total": 57, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 83, "events": [{"event": "general", "label": "Market update", "weight": 20.15, "count": 36}, {"event": "analyst", "label": "Analyst action", "weight": 4.95, "count": 9}, {"event": "earnings", "label": "Earnings", "weight": 3.85, "count": 9}, {"event": "deals", "label": "Deals and strategy", "weight": 1.65, "count": 3}], "positive_events": 19, "negative_events": 5}, "market_context": {"has_market_context": true, "latest_close": 324.99, "latest_week": "2026-07-10", "one_week_move": 2.0, "four_week_move": 21.9, "twelve_week_move": -5.1, "trend_signal": "0", "trend_label": "Trend inactive", "trend_tone": "negative", "market_dynamics": -0.572363, "market_dynamics_buy_signal": false, "relative_strength": 25.711511, "fair_value_gap": 207.6, "fair_value_label": "Materially above fair value", "fair_value_tone": "negative", "expectation_direction": "positive", "expectation_probability": 57.7017, "reaction_label": "Price confirming higher", "reaction_tone": "positive", "market_sentence": "+2.0% over one week, +21.9% over four weeks, trend inactive, and materially above fair value."}, "interpretation": {"label": "Balanced read", "tone": "neutral", "classification": "balanced", "summary": "News tone and price action are not far from neutral.", "confidence": 66, "badges": [], "opportunities": [], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Market source", "count": 11}, {"label": "Stock Titan", "count": 10}, {"label": "TradingView", "count": 5}, {"label": "simplywall.st", "count": 5}, {"label": "Investing.com", "count": 4}, {"label": "MT Newswires", "count": 4}, {"label": "Simply Wall Street", "count": 3}, {"label": "GlobeNewswire", "count": 3}], "tiers": [{"label": "Direct company coverage", "count": 49}, {"label": "Industry context", "count": 8}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 36}, {"label": "Analyst action", "count": 9}, {"label": "Earnings", "count": 9}, {"label": "Deals and strategy", "count": 3}]}, "insights": [{"label": "Weighted tone", "value": "56/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Balanced read", "tone": "neutral", "text": "News tone and price action are not far from neutral."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "83/100 classification confidence."}, {"label": "Company focus", "value": "49", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "1", "tone": "positive", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend inactive", "tone": "negative", "text": "+2.0% over one week, +21.9% over four weeks, trend inactive, and materially above fair value."}, {"label": "Latest direct headline", "value": "Positive", "tone": "positive", "text": "Should Praxis\u2013Remagine Transdermal Patch Collaboration and FDA Review Extension Reshape PRAX Pipeline Expectations?"}], "updated_at": "2026-07-16T15:23:12.594341+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}